Tenet Healthcare Guides FY26 In Line With Estimates

Tenet Healthcare initiated fiscal 2026 guidance, forecasting GAAP earnings of $29.60–$32.27 per share and adjusted earnings of $16.19–$18.47 per share on net operating revenues of $21.50 billion–$22.30 billion. The company’s adjusted guidance is essentially in line with the Bloomberg/RTT consensus (19 analysts) expecting $16.46 EPS on $22.20 billion revenue, and Tenet said revenue from the termination of the CommonSpirit contract is excluded from net operating revenues. Shares were trading modestly higher pre-market at $193.30 (+0.13%).

Analysis

Market structure: Tenet (THC) guiding adjusted EPS $16.19–$18.47 on revenues $21.5–$22.3B (analyst EPS $16.46, rev $22.2B) — guidance in line but explicitly excludes revenue from the CommonSpirit contract termination, implying management is isolating one‑time flows and leaving room for upside to GAAP/adjusted EPS. Direct winners are Tenet equity and creditors if termination proceeds materialize; competitors (HCA, UHS) could lose short‑term volume or pricing leverage where CommonSpirit relationships unwind. Hospital operator bargaining power remains local and fragmented, so share shifts are possible but not automatic.

Risk assessment: Tail risks include adverse CMS reimbursement updates, False Claims Act settlements, or labor inflation (nurse wage inflation >5% YoY) that could compress margins and turn a conservative guide into a miss; regulatory/antitrust scrutiny around contract terminations is a low‑probability, high‑impact event. Time horizons split: immediate reaction (days) likely muted, short term (weeks–months) driven by 10‑Q disclosure of termination proceeds and quarterly cadence; long term (2–3 years) dependent on outpatient migration and cost structure improvements. Hidden dependency: accounting treatment of termination proceeds and litigation reserves — a $200–500M swing could move adjusted EPS by several dollars.

Trade implications: Idiosyncratic upside exists; buy‑or‑add on 3–7% pullbacks within 2–6 weeks to capture re‑rating if termination proceeds hit earnings statements. Relative trades: long THC vs short HCA to isolate Tenet’s contract windfall; use capped option structures (calendar or call spreads) to limit downside. Cross‑asset: expect modest spread tightening in THC bonds on positive surprise and lower equity implied volatility; option skew cheapens once guidance is digested, so front‑month premium is a short‑term hedge.

Contrarian angles: Consensus focuses on in‑line guide; it may be underestimating the optionality from excluded termination revenue — if even half of that flows to pre‑tax income, adjusted EPS could surprise by ~3–8% in FY26. Conversely, market complacency could be punctured by a surprise litigation reserve or adverse accounting, so the trade is asymmetric: limited visible upside versus non‑trivial downside. Historical parallels: hospital operators that flagged one‑time contract exits often saw stock re‑rating only after clear GAAP recognition — patience (6–12 months) matters.

Key Decisions for Investors

• Establish a 2–3% long position in Tenet Healthcare (THC) within the next 2–6 weeks; target 10–15% upside over 6–12 months, set a hard stop‑loss at 8% from cost and tranche purchases on any 4–6% pullback.
• Implement a pair trade: long THC equal dollar exposure vs short HCA (ticker HCA) for 6–12 months to capture idiosyncratic upside from Tenet’s excluded termination proceeds; close if the spread compresses by 50% or after 12 months.
• Buy a capped call spread to express asymmetric upside: purchase Jan 2027 THC 195 calls and sell Jan 2027 235 calls (or nearest liquid strikes), size to ≤0.75% of portfolio capital; max loss = premium, plan to unwind if THC >20% above entry or at 12 months.
• Trim/underweight small regional hospital stocks (e.g., UHS, CYH) by 3–5% reallocating to THC and larger diversified providers; re‑assess if nurse wage inflation exceeds 5% YoY or if any False Claims Act settlements reported >$200M within 90 days.
• Monitor within 30–60 days: Tenet’s 10‑Q disclosure on CommonSpirit termination cash/charge treatment and any CMS IPPS/OPPS rule updates — if termination proceeds are recognized in GAAP operating income, increase THC exposure; if significant reserve/litigation appears, reduce immediately.